X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 14.0 44.6 31.5% View Chart
P/BV x 3.6 3.8 94.3% View Chart
Dividend Yield % 0.4 0.3 129.0%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
CIPLA
Mar-17
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs895622 143.9%   
Low Rs622458 135.7%   
Sales per share (Unadj.) Rs254.6181.9 140.0%  
Earnings per share (Unadj.) Rs39.312.9 305.2%  
Cash flow per share (Unadj.) Rs46.629.3 158.9%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.30.4 89.0%  
Book value per share (Unadj.) Rs160.0155.7 102.7%  
Shares outstanding (eoy) m585.88804.51 72.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 100.3%   
Avg P/E ratio x19.342.0 46.0%  
P/CF ratio (eoy) x16.318.4 88.4%  
Price / Book Value ratio x4.73.5 136.7%  
Dividend payout %6.415.5 41.0%   
Avg Mkt Cap Rs m444,390434,516 102.3%   
No. of employees `00014.023.0 60.7%   
Total wages/salary Rs m17,67826,338 67.1%   
Avg. sales/employee Rs Th10,667.86,349.1 168.0%   
Avg. wages/employee Rs Th1,264.31,143.0 110.6%   
Avg. net profit/employee Rs Th1,645.8449.3 366.3%   
INCOME DATA
Net Sales Rs m149,157146,302 102.0%  
Other income Rs m1,1592,287 50.7%   
Total revenues Rs m150,316148,589 101.2%   
Gross profit Rs m34,34324,758 138.7%  
Depreciation Rs m4,27613,229 32.3%   
Interest Rs m6671,594 41.9%   
Profit before tax Rs m30,55812,222 250.0%   
Minority Interest Rs m500-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,798 422.6%   
Profit after tax Rs m23,01210,354 222.2%  
Gross profit margin %23.016.9 136.1%  
Effective tax rate %24.914.7 169.0%   
Net profit margin %15.47.1 218.0%  
BALANCE SHEET DATA
Current assets Rs m92,06287,370 105.4%   
Current liabilities Rs m66,22333,081 200.2%   
Net working cap to sales %17.337.1 46.7%  
Current ratio x1.42.6 52.6%  
Inventory Days Days10687 121.9%  
Debtors Days Days6862 108.6%  
Net fixed assets Rs m62,919111,567 56.4%   
Share capital Rs m5861,609 36.4%   
"Free" reserves Rs m93,133123,645 75.3%   
Net worth Rs m93,719125,254 74.8%   
Long term debt Rs m1,81436,454 5.0%   
Total assets Rs m162,494209,532 77.6%  
Interest coverage x46.88.7 539.9%   
Debt to equity ratio x00.3 6.7%  
Sales to assets ratio x0.90.7 131.5%   
Return on assets %14.65.7 255.6%  
Return on equity %24.68.3 297.0%  
Return on capital %32.78.5 385.1%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m75,83851,066 148.5%   
Fx outflow Rs m30,22417,678 171.0%   
Net fx Rs m45,61333,388 136.6%   
CASH FLOW
From Operations Rs m32,78623,824 137.6%  
From Investments Rs m-17,870-13,127 136.1%  
From Financial Activity Rs m-19,153-13,239 144.7%  
Net Cashflow Rs m-4,239-2,478 171.1%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 20, 2018 09:51 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SUVEN LIFE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS